TTrialPathMatch Me to Trials
← Back to trials
RecruitingNon-muscle Invasive Bladder Cancer (NMIBC)

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.

Sponsor: Lahey Clinic

You may qualify if…

  • ✓ AUA high-risk bladder cancer1
  • ✓ Received induction BCG or gemcitabine/docetaxel
  • ✓ Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)

You may not qualify if…

  • ✕ High-risk NMIBC within 3 years
  • ✕ Prior induction intravesical therapy
  • ✕ Variant histology
  • ✕ Concurrent upper tract disease

Where it's recruiting

Massachusetts

Burlington

Source: ClinicalTrials.gov · NCT07187063 · last updated 2026-11-03

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invas · TrialPath